Who Owns Lamisil?
Lamisil is owned by Haleon plc, a publicly traded British consumer healthcare company that was spun off from GSK in July 2022. Lamisil was originally developed by Sandoz (now part of Novartis) and approved in 1991. The brand transferred to GSK's consumer health division in 2014 as part of a major asset swap with Novartis, and became part of Haleon when GSK spun off its consumer health business in 2022.
Parent Company
Haleon plc
Acquired
2014
Status
Publicly Traded
Headquarters
Weybridge, United Kingdom
Who Owns Lamisil?
- Parent Company: Haleon plc
- Ownership Type: Wholly owned
- Acquisition Year: 2014
- Company Type: Publicly Traded
- Stock Ticker: LSE: HLN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Lamisil | Haleon plc | Wholly owned |
History of Lamisil
- Founded: 1991
- Founders: Sandoz (now Novartis)
- Acquired by Haleon plc: 2014
Lamisil's active ingredient, terbinafine, was developed by Sandoz researchers in the 1980s as a novel antifungal compound. The drug was first approved as a prescription medication in 1991, representing a significant advancement in antifungal therapy. Terbinafine works by inhibiting squalene epoxidase, an enzyme essential for fungal cell membrane synthesis, making it highly effective against dermatophyte fungi.
Throughout the 1990s, Lamisil gained widespread recognition as one of the most effective treatments for fungal nail infections (onychomycosis) and skin infections. The brand expanded from prescription-only to include over-the-counter formulations for athlete's foot and other common superficial fungal infections. Lamisil's product line grew to include creams, sprays, gels, and oral tablets.
When Novartis was formed through the merger of Sandoz and Ciba-Geigy in 1996, Lamisil became part of Novartis's consumer health portfolio. In 2014, the brand transferred to GSK's consumer healthcare joint venture as part of a major industry restructuring deal between Novartis and GSK. GSK took full control of the venture in 2018.
In July 2022, Lamisil became part of Haleon plc when GSK spun off its consumer healthcare division. Under Haleon's ownership, Lamisil continues to be marketed globally as a trusted antifungal treatment, available over-the-counter in most markets.
About Haleon plc
What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne (sensitivity toothpaste), Panadol (pain relief), Centrum (multivitamins), Advil (ibuprofen), Voltaren (topical pain relief), Otrivin (nasal decongestant), Parodontax (gum health), Polident and Poligrip (denture care), Aquafresh (oral care), and Emergen-C (vitamin C). Products are sold in more than 170 countries.
Is Haleon publicly traded?
Yes, Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on 18 July 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder, and its shares are held primarily by institutional investors.
Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara, who had led the GSK Consumer Healthcare joint venture, became CEO of Haleon at the time of the demerger.
Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China, among other locations. The company sells products in more than 170 countries through a global commercial organization.
How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The company's portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums). The company's strategy is to build global scale in a small number of category-leading brands rather than operate a large number of smaller brands.
Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon, but both companies have been reducing their positions over time. As of early 2026, both GSK and Pfizer have substantially reduced their stakes. The remaining shares are held by institutional investors and public shareholders. The company's board includes a majority of independent non-executive directors.
- Founded: 2022
- Headquarters: Weybridge, Surrey, United Kingdom
- Company Type: Publicly Traded
- Stock: LSE: HLN
Where Is Lamisil Made / Based?
- Headquarters: Weybridge, United Kingdom
- Manufacturing / Operations: United Kingdom, United States, Switzerland, Various international locations
Brands Owned by Haleon plc
Lamisil Ownership: Pros & Cons
Advantages
- +Effective antifungal treatment backed by decades of clinical evidence
- +Available over-the-counter in most markets for convenient access
- +Multiple formulations (cream, spray, gel, oral) for different infection types
- +Trusted brand reputation built over 30+ years
- +Strong global distribution through Haleon's retail and pharmacy networks
Considerations
- -Potential for skin irritation or allergic reactions in some users
- -Oral formulations require prescription and monitoring for liver function
- -Competition from generic terbinafine products and other antifungal brands
- -Extended treatment periods required for toenail fungus
- -Some consumers prefer natural or alternative antifungal treatments
Frequently Asked Questions About Lamisil
Where to Buy
Disclosure: We may earn commission from purchases
Lamisil on AmazonHaleon plc Stock Information
Jobs at Haleon plc
Latest News About Lamisil
Related Articles About Lamisil
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Brand Spin-offs: When Companies Sell Off Their Own Brands
From Kenvue to Kellanova, major corporations are spinning off iconic brands into independent companies. Learn why, how it works, and what it means for consumers.
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.